RNXT - RenovoRx, Inc.

0.8
0.010   1.250%

Share volume: 166,433
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$0.79
0.01
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
17%
Profitability 0%
Dept financing 39%
Liquidity 50%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-9.24%
1 Month
-12.09%
3 Months
-39.85%
6 Months
-19.19%
1 Year
-32.20%
2 Year
-71.53%
Key data
Stock price
$0.80
P/E Ratio 
0.00
DAY RANGE
$0.80 - $0.86
EPS 
-$0.17
52 WEEK RANGE
$0.75 - $1.69
52 WEEK CHANGE
-$33.11
MARKET CAP 
25.426 M
YIELD 
N/A
SHARES OUTSTANDING 
23.987 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
1.99
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$88,250
AVERAGE 30 VOLUME 
$81,704
Company detail
CEO: Shaun R. Bagai
Region: US
Website: www.renovorx.com
Employees: 6
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

RenovoRx, Inc. focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath.

Recent news
loading